LGR5 delta5

CI-VAR-00004934Explore in graph →CIViC 3482

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Oral Cavity Squamous Cell Carcinoma1
LGR5 delta5	(prognostic)	Prognostic	B	Supports Poor Outcome	4	submitted	EID9621 In a clinical trial including 78 patients, expression of delta5 is significantly associated with decreased OS (p = 0.02) and DFS (p = 0.01) by multivariate analysis. PMID 30770730 · Rot et al., 2019 · Open in CIViC	civic
Sarcoma1
LGR5 delta5	(prognostic)	Prognostic	B	Supports Poor Outcome	4	submitted	EID9622 In a clinical trial including 77 patients, low expression of delta5 deletion is significantly correlated with decreased OS (p = 0.026) by multivariate analysis and with decreased RFS (p = 0.043). More… (full text at CIViC) PMID 21978106 · Rot et al., 2011 · Open in CIViC

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.